YD Bio Limited Ordinary Shares
YDES
Get informed when a big investor buys or sells
+ FollowMarket Cap$225.95M
Close$
$-0.10
103.7% downside
Current Fair Value
103.7% downsideOvervalued by 103.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $225.95 Million |
|---|---|
| Enterprise Value | $223.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | -0.12 |
| Outstanding Shares | 3,409,483 |
Return
| Return on Equity | -66.49% |
|---|---|
| Return on Assets | -29.57% |
| Return on Invested Capital | -33.22% |
Valuation & Multiples
| P/E Ratio | -1.96 |
|---|---|
| PEG | 1.73 |
| Price to Sales | - |
| Price to Book Ratio | 2.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -74.83 |
| Enterprise Value to Net Income | -76 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.43%▲ 0.19% |
|---|---|
| Total Invested | $639,571▼ 47.93% |
| Investors Holding | 12▲ 4.00% |
ESG Score
No data
About YD Bio Limited Ordinary Shares
4 employees
CEO: Ethan Shen Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of ...